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s u m m a r y
Background: Vitamin C may enhance nitric oxide (NO) production through stepwise reduction of dietary
nitrate (NO3) to nitrite (NO2) to NO. The combined effect of vitamin C and NO3 supplementation is
relatively unexplored in untreated hypercholesterolemia.
Aims: We aimed to examine whether co-administration of vitamin C and nitrate for 4-weeks would
improve endothelial function (primary outcome), plasma NO metabolites, oxidative stress, and blood
lipids (secondary outcomes).
Methods: Subjects 50e70 years of age with low density lipoprotein (LDL) > 130 mg/dL and RHI 2 were
enrolled in this randomized double-blind crossover study. Subjects were assigned to two 4-week sup-
plementation treatments starting with 70 ml of concentrated beetroot juice (CBJ) with 1000 mg of
vitamin C (NC) or CBJ with matched placebo (N), then switched to alternate treatment following 2-week
washout. The change in reactive hyperemia index (RHI), sum of plasma NO metabolites (NO2 þ NO3
(NOx)), oxidized LDL (oxLDL), and serum lipids were assessed at baseline and at 4-weeks of each
treatment period.
Results: Eighteen subjects (11M:7F) completed all study visits. No significant treatment differences were
observed in RHI change (N: 0.21 ± 0.12; NC: 0.20 ± 0.17; p ¼ 0.99). Secondary analysis revealed that a
subgroup of NC subjects who started with a baseline RHI of <1.67 (threshold value for ED) had greater
improvements in RHI compared to subjects with RHI >1.67 (1.23 ± 0.15 to 1.96 ± 0.19; n ¼ 8 vs. 1.75 ± 0.11
to 1.43 ± 0.10; n ¼ 8; p ¼ 0.02). Compared to N, NC experienced a significant increase in plasma NOx (N:
94.2 ± 15.5 mmol/L; NC: 128.7 ± 29.1 mmol/L; p ¼ 0.01). Although there was no significant difference in
oxLDL change between treatments (N: 1.08 ± 9.8 U/L; NC: 6.07 ± 9.14 U/L; p ¼ 0.19), NC elicited
significant reductions in LDL (N: 2.2 ± 2; NC: 10.7 ± 23; p ¼ 0.049), triglycerides (N: 14.6 ± 43;
NC: 43.7 ± 45; p ¼ 0.03), and no change in serum high density lipoprotein. Within treatment group
comparisons showed that only NC reduced oxLDL significantly from baseline to 4 weeks (p ¼ 0.01).
Conclusions: No between intervention differences were observed in RHI. RHI only improved in NC
subjects with ED at intervention baseline. Four weeks of NC enriched the NO pool and promoted
reduction of blood lipids and oxidative stress in subjects with hypercholesterolemia. These preliminary
findings highlight a supplementation strategy that may reduce the progression of atherosclerotic disease
and deserves further attention in studies using flow mediated dilation methods.
Clinical trial registration: www.clinicaltrials.gov (NCT04283630).
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Dietary inorganic nitrate supplementation leads to increased
nitric oxide (NO) generation and has received attention for its po-
tential role in reversing endothelial dysfunction (ED) [1e3]. Low
serum and tissue NO status is a hallmark of ED that is associated
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with most cardiovascular risk factors (CVRFs) and cardiovascular
events [4e6]. NO is a vasodilator and anti-atherogenic molecule that
maintains vascular homeostasis and modulates in vitro lipid per-
oxidation reactions [7]. NO presents in circulation from two path-
ways but direct in vivomeasurement of NO cannot bemeasured due
to its short half-life (milliseconds) [8e10]. NO is rapidly auto-
oxidized to nitrate and nitrite in circulation when it is synthesized
from its primary endogenous precursor (arginine) by endothelium
nitric oxide synthase (eNOS) enzyme [11]. In the presence of CVRFs,
dietary nitrate provides an exogenous source and alternate pathway
of NO generation when eNOS is compromised [11]. Thus, in both
pathways, nitrite and nitrate act as stable end products that reflect
total systemic NO concentrations [10] and their plasma concentra-
tions can be used as surrogate measures of vascular NO bioavail-
ability [4]. Combined measurements of NO metabolic pathway
products (nitrate þ nitrite) are termed as NOx [12].
There is a growing interest in examining the utility of dietary
nitrate on the management and reversal of ED and attenuating
oxidative stress biomarkers [13,14]. Oxidative stress is a key
mediator contributing to the promotion of ED and atherosclerosis
(AS) in subjects with CVRFs, and may be counteracted with stra-
tegies designed to preserve endothelial NO [15e17]. Promising
findings from preclinical studies reported that inorganic nitrate
supplementation was able to reduce well-established markers of
oxidative stress, such as malondialdehyde and pro-inflammatory
cytokines [18,19]. To our knowledge, few clinical trials have inves-
tigated the effect of inorganic nitrate supplementation on different
markers of oxidative stress [1,20,21]. One of these studies reported
a trend in oxLDL reduction in untreated hypercholesterolemic
subjects following 6 mmol of dietary nitrate supplementation [1].
Borsa et al. [12] reported that systemic NO was negatively corre-
lated with circulating oxLDL in hyperlipidemic elderly patients.
Further studies are needed to better understand the use of dietary
nitrate in relation to circulatory oxLDL in hypercholesterolemia and
to further elucidate the dietary nitrate benefit on oxidative stress
associated ED [1].
Vitamin C plays a role in enhancing the exogenous NO pathway
through the stepwise reduction of dietary nitrate to nitrite and then
NO [22]. Under hypoxic and acidic condition in the blood and
gastric lumen, the presence of vitamin C may augment the second
reduction step of nitrite to NO [23]. The interaction between nitrate
and vitamin C has been recently described in the literature and has
indicated that vitamin C acts as an enhancer to catalyze the con-
version of acidified nitrite to NO, thus, increasing the NO pool
[23e27].
NO2e þ Hþ / HNO2
2 HNO2 þ vitamin C / 2  NO þ dehydroascorbic acid þ2 H2O
Although dietary nitrate and vitamin C have been indepen-
dently linked to augmentation of NO and reducing oxidative stress,
there is a paucity of data that have examined the combined sup-
plementation effect on cardiovascular health among patients with
CVRFs. Recently, Ashor et al. (2019) [22] demonstrated a significant
synergistic effect following a single co-administered dose of
vitamin C with dietary nitrate in healthy individuals. Results
showed improvements in arterial stiffness as measured by pulse
wave amplitude, 3-nitrotyrosine concentrations, and blood pres-
sure compared to vitamin C or nitrate given separately. However,
this combination did not improve endothelial function in all groups
as measured by post-occlusion reactive hyperemia. Studies of
longer duration designed to provide daily combined dosing of these
supplements interventions have yet to be conducted.
We aimed to examine whether co-administration of vitamin C
and nitrate for 4-weeks would improve markers of endothelial
function (primary outcome), plasma NO metabolites, oxidative
stress, and blood lipids (secondary outcomes). On the basis of their
complementary mode of action to augment NO and improve
endothelial function, we hypothesized that daily co-administration
of inorganic NO3- and vitamin C for 4-weeks would elicit a greater
improvement in endothelial function as a result of changes in
reactive hyperemia index (RHI) score and other blood biomarkers
such as NO metabolites, oxLDL, and lipid profile compared to ni-
trate alone.
2. Materials and methods
2.1. Subjects
Male and female non-smokers between the age of 50 and 70
with a body mass index (BMI) of 18.5e34.9 kg/m2 and high LDL
concentrations (>130 mg/dL) were enrolled. This age range was
chosen to target individuals more prone to hypercholesterolemia
and endothelial abnormalities [28]. The BMI range was selected to
examine whether our intervention would have different effects on
different BMI classes.
Subjects were excluded if receiving lipid lowering therapy,
multivitamin supplements exceeding recommended dietary
allowance (RDA), or on hormone replacement therapy, clonidine,
proton pump inhibitors (PPI), or antibiotic medications. Moreover,
subjects who consumed greater than 6 servings of alcohol per
week, performed resistance or aerobic training for more than 1-
hour four times per week, or participated in other clinical in-
terventions within the previous 30 days were excluded from the
study. Subjects with a documented history of CVD, diabetes mel-
litus, chronic inflammatory disease, celiac disease, uncontrolled
hypertension, hepatic or renal disease, and active cancer were not
included in the study. Final enrollment decisions were contingent
upon having an RHI 2.
This study was approved by the university Institutional Review
Board, and the informed written consent was obtained from all
subjects prior to engaging in baseline measures. All institutional
and governmental regulations concerning the use of human vol-
unteers were followed during this research. All study visits were
Abbreviations
AS atherosclerosis
CBJ concentrated beetroot juice
CVD cardiovascular disease
CVRFs cardiovascular risk factors
ED endothelial dysfunction
eNOS endothelium nitric oxide synthase
HDL high density lipoprotein cholesterol
LDL low density lipoprotein cholesterol
N dietary nitrate supplementation alone




NOx sum of nitric oxide metabolites
oxLDL oxidized low density lipoprotein
RH-PAT reactive hyperemia peripheral artery tonometry
RHI reactive hyperemia index
TC total cholesterol
TG triglycerides
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conducted in the Center for Clinical and Translational Sciences
(CCTS), University of Kentucky, from February 2019 to September
2019. This study was registered with ClinicalTrials.gov
(NCT04283630).
2.2. Study design and randomization
This was a 10-week double-blind, placebo-controlled crossover
study. Randomization was conducted by the Investigational Drug
Service (IDS) at University of Kentucky. IDS prepared a randomi-
zation list treatment sequence. As subjects enrolled, they received
their intervention order and blinded supplement assignment.
Vitamin C and its placebo packaging were identified by the letter
“A” or “B” and therefore blinded to subjects and investigators. The
blinded supplements were then provided to the study coordinator
with the treatment allocation in a sealed envelope. The preparation
and labeling of the vitamin C and its placebo were performed in
such a way that both capsules were identical in shape, color, and
size to ensure adequate blinding of both subjects and investigators.
2.3. Study protocol
2.3.1. Screening visits
At screening visit 1 a phone screening or a face-to face interview
was performed to gauge subject's interest followed by assessing
BMI and screening for inclusion and exclusion criteria. At screening
visit 2 a non-invasive technique called Reactive Hyperemia Pe-
ripheral Artery Tonometry (RH-PAT) was employed to only include
subjects with RHI score 2. RH-PAT is intended for detection of ED
since the decline of endothelium-derived NO bioavailability is re-
flected by impaired RH-PAT vascular responses [29,30]. The main
advantages of this system are that it is operator independent, less
expensive, provides automated analysis, and easily performed [30].
In addition, validation studies reported that lower RHI is associated
with several cardiovascular risk factors [31e34].
2.3.2. Study visits
Subjects completed 4 visits as described in Fig. 1. Each visit in-
cludes anthropometric measures, blood pressure, vascular testing,
and blood collection. Vascular testing was defined as measures of
RHI ratio (primary outcome). Venous blood samples were collected
at baseline and endpoint visits of each intervention period
following an overnight fast. Plasma was used to measure nitrate
and nitrite, vitamin C, oxLDL, total cholesterol (TC), triglycerides
(TG), low-density lipoprotein (LDL), and high-density lipoprotein
(HDL) concentrations. Our washout length was chosen based on
previous work showing that a 2-week washout returned NO me-
tabolites and vitamin C to baseline concentrations [35,36].
Prior to each visit, including screening visit stage 2, subjects
were asked to perform the following to prepare for vascular testing:
1) consume a low-nitrate diet for 48 h [35]; 2) refrain from taking
anti-hypertensive agents and long-acting vasoactive medications
including steroids, beta-blockers, antacids, anticoagulants, calcium
channel blockers, angiotensin converting enzyme inhibitors (ACE-
inhibitors), and aspirin for 24 h; 3) abstain from alcoholic bever-
ages, coffee, high fat foods, chewing gum; 4) abstain from strenuous
exercise for 24 h [1]; and 5) fast for 12 h prior to study visit [32].
Throughout the intervention periods, subjects were instructed
to avoid high vitamin C foods and maintain their usual dietary
patterns throughout the duration of the washout period. At the
beginning of the study, subjects were provided with a list of high
vitamin C foods and vitamin C fortified foods to avoid during both
intervention periods. Dietary intake was assessed via 24-hr dietary
recall. Three 24-hour dietary recalls were collected and analyzed
using Nutrition Data System for Research (NDSR, Version 2019,
University of Minnesota, Minneapolis, MN, USA) at midpoint of
each interventional period, covering 1weekend and 2weekdays for
a total of 6 recalls.
2.4. Endothelial function measurement
Reactive hyperemia peripheral artery tonometry (RH-PAT) was
used to assess endothelial function in peripheral arteries. RH-PAT is
a non-invasive technique comprised of two finger plethysmo-
graphic probes connected to the EndoPAT-2000 device (Itamar
Medical, Caesarea, Israel) to measure changes in arterial pulsatile
volume induced by reactive hyperemia. EndoPAT tests occurred at
approximately 10 AM at each visit. Measures were performed in a
temperature-controlled room (70e75 F [21e24 C]) and the sub-
ject was asked to lie in a supine position for the procedure [32].
RH-PAT examination included three stages: pre occlusion, oc-
clusion, and post occlusion. A manual blood pressure cuff was
placed on the upper arm of the non-dominant hand (occlusion
arm) to initiate PAT measurement. Then, two plethysmography
probes were placed on both index fingers of each hand and inflated.
Subjects were asked to stay as still as possible during the entire
Fig. 1. Schematic representation of the study design. NO3: inorganic nitrate from concentrated beetroot juice dietary supplement.
R. Basaqr, M. Skleres, R. Jayswal et al. Clinical Nutrition 40 (2021) 1851e1860
1853
testing period. Following a 10 min rest period, the blood pressure
cuff was inflated manually to suprasystolic pressures by adding at
least 60mmHG above systolic BP for fiveminutes. The cuff was then
deflated quickly and the EndoPAT device continued recording pulse
wave response for five minutes [29,37]. The RHI value was calcu-
lated automatically by dividing post-occlusion pulse wave ampli-
tude (PWA) to the pre-occlusion value of PWA of the same arm,
normalized to the control arm, and then multiplied by baseline
correction factor [29,37].
2.5. Plasma biomarkers
Fasting blood samples were drawn by trained staff at the Uni-
versity of Kentucky's CCTS immediately following vascular testing.
Plasma samples were stored at 80 C for analysis at a later time.
Plasma nitrate and nitrite were analyzed using Parameter™ Assay
Kit KGE001 (R&D Systems, Minneapolis MN, USA). The result was
read using the Griess Reaction @ 540e570 nM [38]. Plasma vitamin
C concentrations were analyzed using high performance liquid
chromatography (HPLC, ESA Inc.). Plasma oxidized LDL was
measured using ELISA kit (Mercodia kit, Uppsala, Sweden) based on
the monoclonal antibody 4E6 [39]. Fasting plasma TG and TC con-
centrations were determined enzymatically using the Specific
Clinical Chemistry Analyzer. Heparine manganese chloride pre-
cipitation of plasma was used to measure high-density lipoprotein
(HDL) cholesterol. LDL concentration was calculated by the Frie-
dewald formula [40].
2.6. Dietary supplementation
The nitrate supplement was a commercially available beetroot
juice beverage (Sport Beet IT shot, Heartbeet Ltd). Sport Beet IT was
a concentrated beetroot juice (CBJ) (70 ml) that delivered an
average of 400e450 mg (~6.4 mmol) dose of inorganic nitrate per
the 70 ml serving [2]. The dietary nitrate dose was chosen due to
documented safety and efficacy in previous studies that have
shown improvements in vascular health or a reduction in blood
pressure with no signs of toxicity [41e43]. Vitamin C (Nature Made
®), and the placebo (corn starch) were provided as supplement
capsules based on the randomization order. The selected dose of
Fig. 2. Consort diagram of the progress through the phases of a crossover randomized trial of two treatment groups.
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vitamin C (1000 mg) was based on observations from a previous
meta-analysis and systematic review reporting a minimum of
1000 mg of vitamin C per day elicited an improvement in endo-
thelial function [44]. The study coordinator instructed subjects to
self-administer CBJ for 7 days a week at the same time by mouth
daily during the morning hours and then consume 2 capsules
(1000 mg of vitamin C or placebo) one hour later. Supplement
adherence was assessed by counting unused capsules and CBJ
bottles at each intervention endpoint.
2.7. Statistical analysis
Using the nQuery Advisor program, sample size calculations
were based on the work of Kwak et al. (2012) [45]. Based on these
data, nineteen subjects were needed for 80% power with a two-
sided p-value of 0.05 set for statistical significance. Distribution
of continuous variables were examined by ShapiroeWilk test.
For within group comparisons, paired t-tests (for normally
distributed data) and Wilcoxon signed rank-test (for non-normally
distributed data) were employed using data at baseline and 4-
weeks for two interventional periods separately. Changes in mea-
sures over the 4-week period were assessed by calculating the
difference from baseline to 4 week in each treatment
(change¼ endpoint-baseline). For between group comparisons, the
treatment effect (D) was evaluated by a two-sided one-sample t-
test based on the mean of the differences between the two changes
for each pair (change during NC-change during N) [46].
Additionally, based onwork byWellek et al. [47], nonparametric
Wilcoxon tests were used to verify whether there were any carry-
over effects from one treatment period to another. An independent
sample t-test was used to assess the changes in RHI between high-
responders and low-responders regardless of treatment group.
Linear mixed models were used to assess potential interaction ef-
fects of variables such as BMI and BP medication, sex, and age with
dependent variables. Pearson and Spearman correlations were
used to assess the relationship between dependent variables. Sta-
tistical analyses was performed using Statistical Package for Social
Sciences (SPSS) software (version 22, IBM, Armonk, NY). Data are
presented as means ± standard error of the mean (SEM).
3. Results
3.1. Subjects
Of the 23 subjects who enrolled, 18 completed both in-
terventions and all study visits (Fig. 2). Further explanation of
subject attrition is found in Fig. 2. All baseline characteristics are
shown in Table 1. The interventions were generally well-tolerated
with no reports of severe adverse effects. Analyses of three di-
etary recalls at each treatment period indicated no significant dif-
ferences in dietary nutrient intake or dietary patterns (data not
shown).
3.2. Adherence and subject response to supplementation
Based on returned CBJ and capsule bottles and supplement di-
aries, more than 99% of CBJ and 98% of vitamin C distributed in both
interventional periods were reported to be ingested.
3.3. Nitrate, nitrite concentrations
Significant differences were observed in the mean change of
plasma nitrate (D ¼ 50.02y, p < 0.01) and nitrite (D ¼ 0.03y,
p ¼ 0.03) between both treatment groups (Table 2). Within treat-
ment group comparisons showed that endpoint plasma nitrate
concentrations were significantly increased compared to baseline
(p < 0.001) (Table 2). Likewise, the endpoint plasma nitrite con-
centrations were significantly increased after N (p ¼ 0.006) but did
not increase after 4 weeks of NC (p ¼ 0.23) (Table 2). The change of
plasma NOx status between treatments was significant (N:
94.24 ± 19.5 mmol/L; NC: 128.7 ± 29.1 mmol/L; p ¼ 0.01). Within
treatment group comparisons revealed that N and NC endpoint
NOx measures significantly increased over time (p < 0.001) (Fig. 3).
Secondary analysis indicated that post-supplementation changes in
plasma NOx concentration correlated significantly with changes in
plasma vitamin C following NC treatment (r ¼ 0.49, p ¼ 0.04) with
no correlation seen following N treatment (r ¼ 0.29, p ¼ 0.26).
Table 1
Baseline characteristics.
Variables Treatment N Treatment NC Total
(n ¼ 9) (n ¼ 9) (n ¼ 18)
Male sex, n (%) 3 (33%) 4 (44%) 7 (39%)
Age (years) 58 ± 1 59 ± 2 59 ± 1
BMI (kg/m2) 29.6 ± 1 27.1 ± 1.0 28.3 ± 0.8
Subjects on BP
medications n (%)
3 (33.3%) 3 (33.3%) 6 (33.3%)
Plasma vitamin C (mg/dL) 0.73 ± 0.2 0.88 ± 0.2 0.81 ± 0.1
Plasma NO3 (mmol/L) 13.4 ± 1.8 18.5 ± 2.8 16.0 ± 1.7
Plasma NO2 (mmol/L) 0.44 ± 0.1 0.46 ± 0.1 0.45 ± 0.1
Plasma NOx (mmol/L) 14.4 ± 1.8 18.9 ± 2.8 16.7 ± 1.7
RHI 1.55 ± 0.1 1.66 ± 0.1 1.60 ± 0.1
Plasma oxLDL (U/L) 71.7 ± 2.9 70.1 ± 4.2 75.9 ± 2.9
Plasma TC (mg/dL) 235.4 ± 6.6 249.1 ± 16.1 242.3 ± 8.6
Plasma LDL (mg/dL) 135.3 ± 6.1 167.9 ± 13.7 160.6 ± 7.5
Plasma HDL (mg/dL) 55.1 ± 2.2 54 ± 4.0 54.56 ± 2.2
Plasma TG (mg/dL) 119.2 ± 16 136 ± 18 127.6 ± 11.9
BMI: body mass index; BP: blood pressure; NO3: nitrate; NO2: nitrite; NOx: nitric
oxide metabolic pathway products (nitrate (NO3) þ nitrite (NO2)); RHI: reactive
hyperemia index; TC: total cholesterol; LDL: low-density lipoprotein; HDL: high-
density lipoprotein; TG: Triglycerides. Quantitative variables were described as
the mean ± SEM. Data were analyzed using independent t-test (p > 0.05) and values
were not significantly different between treatments at baseline.
Table 2
Response to 4-week supplementation with N and NC.
Value Time point N NC
Plasma
NO3 (mmol/L)
Baseline 15.6 ± 1.3 16.6 ± 1.9
Endpoint 94.2 ± 15.6 145.3 ± 29.6
Change 1 78.6 ± 15.4* 128.7 ± 29.1*
Change 2 (D) 50.02y
Plasma
NO2 (mmol/L)
Baseline 0.42 ± 0.05 0.45 ± 0.06
Endpoint 0.49 ± 0.05 0.49 ± 0.06
Change 1 0.07 ± 0.02* 0.04 ± 0.03
Change 2 (D) 0.03y
Plasma
Vitamin C (mg/dL)
Baseline 0.81 ± 0.10 0.77 ± 0.10
Endpoint 0.66 ± 0.09 1.2 ± 0.13
Change 1 0.15 ± 0.12 ±0.16*
Change 2 (D) 0.58y
Plasma
NO3 (mmol/L)
Baseline 15.6 ± 1.3 16.6 ± 1.9
Endpoint 94.2 ± 15.6 145.3 ± 29.6
Change 1 78.6 ± 15.4* 128.7 ± 29.1*
Change 2 (D) 50.02y
Plasma
NO2 (mmol/L)
Baseline 0.42 ± 0.05 0.45 ± 0.06
Endpoint 0.49 ± 0.05 0.49 ± 0.06
Change 1 0.07 ± 0.02* 0.04 ± 0.03
Change 2 (D) 0.03y
Plasma
Vitamin C (mg/dL)
Baseline 0.81 ± 0.10 0.77 ± 0.10
Endpoint 0.66 ± 0.09 1.2 ± 0.13
Change 1 0.15 ± 0.12 ±0.16*
Change 2 (D) 0.58y
NO3: nitrate; NO2: nitrite. Change 1: the mean difference between baseline and
endpoint within treatment group. Values are reported as means ± SEM. *(p-val-
ue0.05, Paired t-test). Change 2: the mean difference between treatments. Data for
delta absolute value were analyzed using one sample t-test, yp < 0.05.
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3.4. Vitamin C concentrations
There was a significant difference in plasma vitamin C change
between the treatments (D ¼ 0.58 y, p < 0.001). Within treatment
group comparisons showed that plasma vitamin C concentrations
increased significantly over time following 4-week administration
of NC (Table 2).
3.5. Endothelial function
For our primary outcome, there were no treatment group dif-
ferences in RHI change (N: 0.21± 0.12; NC: 0.20± 0.17; p > 0.05). No
evidence of carryover effect was observed from one treatment
course to the other (p ¼ 0.64). Within treatment group compari-
sons, revealed that RHI scores over time did not change signifi-
cantly in either treatment group (NC: p¼ 0.24; N: p¼ 0.09) (Fig. 3).
Secondary analysis revealed that some subjects responded
greater than others to NC treatment. Subjects were grouped into
“high-responders” and “low-responders” based on their RHI
response to NC treatment. High-responders (n ¼ 8) demonstrated
significant increases in RHI in response to NC (1.23 ± 0.15 to
1.96 ± 0.19; p < 0.01), while the low-responders (n ¼ 8) had a
significant decrease in RHI (1.75 ± 0.11 to 1.43 ± 0.10; p < 0.01).
Significant differences were observed between RHI baseline scores
in high-responders and low-responders (p ¼ 0.02) (Fig. 4). No
notable interactions were detected among demographics and
Fig. 3. Functional and circulatory markers in response to N and NC interventions. RHI score (n ¼ 16) (A), NOx: nitric oxide metabolites (n ¼ 18) (B), oxLDL: plasma oxidized low-
density lipoprotein (n ¼ 18) (C). (N): inorganic nitrate and vitamin C placebo or (NC): inorganic nitrate and active vitamin C (1000 mg). Data were analyzed using Paired t-test for
RHI and oxLDL, and Wilcoxon-test for plasma NOx, *p  0.05. D ¼ mean change between treatments. Data were analyzed using one sample t-test for delta absolute value, yp < 0.05.
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baseline characteristics between the two treatment groups
(sequence 1: N-NC and sequence 2: NC-N) in terms of age, BMI,
gender, RHI, number of subjects on BPmedication, vitamin C status,
and NO metabolite concentrations. Two subjects who started NC
treatment were excluded from RHI analysis due to poor RHI signals
at endpoint.
3.6. Oxidized LDL and blood lipids
Compared to N, there was no significant differences observed in
the change of plasma oxLDL following NC (N: 1.08 ± 2.3 U/L;
NC: 6.07 ± 2.1 U/L; p ¼ 0.19). Within treatment group compari-
sons revealed that NC endpoint oxLDL was significantly lower than
baseline (p ¼ 0.01) (Fig. 3). However, N endpoint oxLDL showed no
change over time (p ¼ 0.64).
Fasting lipid profile analysis indicated that the mean change in
lipids was significantly different following NC and N treatments for
LDL (N: 2.2± 3.5; NC:10.67± 5.4; p¼ 0.049) and TC (N: 0.17± 5.3;
NC: 16.06 ± 6.1; p ¼ 0.05). Serum HDL was unaltered between
treatment groups (N: 0.05 ± 0.8; NC: 0.33 ± 1.5; p ¼ 0.81). No
treatment carryover was evident in LDL (p ¼ 0.78), TC (p ¼ 0.73),
and HDL (p ¼ 0.93) analyses. However, there was a significant
carryover effect in TG (p ¼ 0.03). As a result of this effect, we only
compared period one data for triglyceride changes between the
two treatments. We demonstrated a significant difference in the
mean change of TG between treatments (N: 14.6 ± 14.2;
NC: 43.7 ± 14.9; p ¼ 0.01). Within treatment group comparisons
showed no change in TC (p ¼ 0.97), LDL (p ¼ 0.52), TG (p ¼ 0.33),
and HDL (p ¼ 0.95) from pre-to post following N treatment. In
contrast, there were significant decreases in TC (p ¼ 0.02) and TG
(p ¼ 0.02) with a trend towards a reduction in LDL concentrations
from pre-to post following NC (p ¼ 0.06) (Fig. 5). HDL did not
change by time after NC treatment (p ¼ 0.83) (Fig. 5). Secondary,
exploratory analysis demonstrated that changes in plasma oxLDL
correlated significantly with changes in plasma LDL following both
NC and N treatments (p < 0.01).
4. Discussion
4.1. Summary of the main findings
NC did not improve RHI but significantly increased NOx and
reduced blood lipids. Secondary analyses included subgroup and
within groups comparisons. RHI improved only in a subgroup of
subjects with RHI values indicative of ED. Within treatment group
comparisons revealed that oxLDL was reduced over time only in the
NC intervention.
4.2. Reactive hyperemia index
There were no significant differences in RHI between treatment
interventions. This is contrary to previous data that showed a
positive improvement in coronary endothelial function measured
by flow mediated dilation (FMD) following 4e6 weeks adminis-
tration of inorganic NO3 in subjects with CVRFs [1,2,30,48,49].
However, previous work by Ashor et al. has shown no effects of
nitrate combined with vitamin C on endothelial function using
laser Doppler measurements [22]. Comparisons between our
findings and the findings of others should be interpreted carefully
since these studies used different techniques to measure endo-
thelial function. The absence of a significant change in RHI in the
present study may have many other explanations. First, the hy-
peremic response in microcirculation beds is partly dependent on
NO [50] and other non-endothelium-dependent regulators [51,52]
while FMD response in conduit arteries is mainly NOmediated [53].
Thus, it has been suggested that RH-PAT may not be sensitive
enough to detect the influence of lifestyle modifications that target
NO pathway on microvascular beds [34,37,51]. An additional
explanation may be that the baseline RHI values of some subjects
were greater than 1.67. An RHI value below 1.67 was established by
EndoPAT as the threshold value to define subjects with coronary ED
[54]. Therefore, subjects with RHI baseline scores greater than this
cut point value may be less responsive to improvements in endo-
thelial function. In our secondary subgroup analyses of RHI, it was
shown that the eight “high responder” subjects who showed an
individual increase in RHI following NC treatment (~60% im-
provements from baseline) had low baseline mean of RHI score
below the threshold value of 1.67. Fifty percent of the high re-
sponders achieved an increase in RHI to normal or above normal
values. These observations add novel findings and add to the work
from others that noticed substantial RHI improvements following
dietary interventions in subjects with ED [55,56].
While this was the first study to examine the relationship be-
tween RHI and inorganic nitrate supplementation with and
without vitamin C supplementation, wewere not able to verify if all
subjects took vitamin C exactly one hour following CBJ consump-
tion. Proper timing of vitamin C ingestion 1 h after nitrate dosing is
thought to be important to permit adequate nitrate to enter the
enterosalivary circulation, thereby maximizing the reduction of
nitrite to NO in the gastric cavity as vitamin C consumed [57]. We
acknowledge that our findings may also suggest that subgroup
responders adhered with the timing of vitamin C ingestion more
than low responders.
4.3. Circulatory biomarkers
As expected, the 4-week NC intervention yielded significant
differences in NO3 and NO2 concentrations and reflect increased
capacity for NO production compared to N. The approximate 2-fold
increase in plasma NOx in NC compared to N support align with
previous studies suggesting that vitamin C acts as a potent reducing
agent to support nitrite reduction from the exogenous NO pathway
[24e28]. These findings are not alignedwith recent crossover study
of Ashor et al. [22] who found no modifying effect of vitamin C on
plasma NO metabolites following acute dose of potassium nitrate
(5.1e8.7 mmol) ingestion combined with vitamin C (20 mg/kg) in
healthy individuals. This disparity could be due to the shorter
duration of their study and the differences in the population
Fig. 4. Change of RHI over time following NC treatment between high-responders and
low-responders. RHI score response was compared between high-responders (n ¼ 8)
and low-responders (n ¼ 8) before and after 4 weeks of NC. RHI: Reactive hyperemia
index. Subjects with greater change score in NC were defined as high responders. Data
were analyzed using independent sample t-test to assess RHI baseline score between
high-responders and low-responders, *p  0.05.
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studied. In addition, our 8.8 fold increase in plasma nitrate
following NC was greater than Velmurugan and colleagues [1] who
examined a similar nitrate dosage (~6 mmol) alone and reported a
7.5 fold nitrate increase in untreated hypercholesterolemia
patients.
In the present study, we did not observe between intervention
differences in oxLDL. Within group analysis of the N intervention
offer no evidence of oxLDL reduction and are consistent with pre-
vious work by Velmurugan et al. (2015) [1] who found no nitrate
induced changes in oxLDL in untreated hypercholesterolemic
adults. In contrast, we observed a significant within group reduc-
tion in oxLDL (6.07 U/L) as a result of the NC intervention. These
findings are in accordance with recent work reporting a synergistic
effect of a single combined dose of nitrate and vitamin C on the
oxidative stress marker 3-nitrotyrosine [22]. As LDL peroxidation
and reduced NO synthesis are the two characteristic features of ED,
and share significant antagonistic roles in overall vascular health, it
may be that any observed benefit of NC on oxLDL may be driven by
NOx changes interacting with oxidants on the vascular wall [16].
This speculation requires further study and greater statistical po-
wer as the capacity of both bioactive substances as donors of NO
may have a direct effect on attenuating the lipid peroxidation re-
action [12].
Moreover, we observed the NC intervention resulted in sub-
stantial reductions in TC (16.1 mg/dL or 6.6%), LDL (10.7 mg/dL
or 6.6%), and TG (43 mg/dL or 32%). These findings are of
Fig. 5. Serum lipid profile response to N and NC. TC: Total cholesterol (n ¼ 18) (4A), LDL: low-density lipoprotein (n ¼ 18) (4B), HDL: high-density lipoprotein (n ¼ 18) (4C), and TG:
triglycerides (n ¼ 9) (4D). (N): inorganic nitrate and vitamin C placebo or (NC): inorganic nitrate and active vitamin C (1000 mg). Data were analyzed using Paired t-test for all lipid
profile parameters, *p  0.05. D ¼ mean change between treatments. Data were analyzed using one sample t-test for the absolute delta value, yp < 0.05.
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particular interest because of both the magnitude of change
observed and how they compare with a recent meta-analysis of
vitamin C treatment in hypercholesterolemic adults [58]. In this
meta-analysis, thirteen trials found that TC, LDL, and TG decreased
by 10.76 mg/dL (4.5%), 7.9 mg/dL (5%), and 20.1 mg/dL (8.8%),
respectively. In the present study, nitrate appeared to modify and
improve the lipid lowering effect of vitamin C. Our NC findings can
also be compared to a previous study [59] that combined a 30 day
inorganic nitrate administration along with the antioxidant haw-
thorn berry to reduce TG concentrations. The TG lowering effect
(32%) seen in our work was similar to the percentage of TG
reduction (27%) shown by Zand et al. [59]. Collectively, the im-
provements in blood lipids from our work and others suggest that
NO3 supplementation with the addition of vitamin C (or other
nutraceutical antioxidants), may be a valuable dietary approach to
combat dyslipidemia which could positively impact cardiovascular
health [60,61]. The exact mechanism of action to explain the serum
lipids findings remains to be determined, but may be partially
explained by complementary antioxidant effects of both supple-
ments that work in concert to decrease oxidative stress [58,62e64].
4.4. Strengths and limitations
This work has many strengths including study designwith strict
inclusion and exclusion criteria and high supplement adherence.
Furthermore, the significant increase of plasma NO metabolites
from baseline with or without vitamin C confirmed excellent
adherence with CBJ and agree with previous findings that total
systemic NO bioavailability is strongly influenced by changes in
dietary nitrate in subjects with CVRFs [1,65]. There are also limi-
tations to consider when interpreting results. The major limitation
was the small sample size that may have limited our ability to
observe significant RHI differences between treatments or poten-
tial interactions between the dependent and independent vari-
ables. Although we observed differences between N and NC in most
dependent variables, comparison interpretations should be made
cautiously. A number of exploratory analyses of secondary outcome
variables were conducted for which the study was not powered.
Another limitation is that not all the subjects enrolled the study had
RHI <1.67. In addition, this study was not designed to examine the
effect of vitamin C alone, therefore, it is unknown if systemic NO
accumulation from NC has a direct effect on lipids and oxidative
biomarkers or if the direct beneficial effect is explained by vitamin
C supplementation.
5. Conclusion
Four weeks of NC intervention improved endothelial function as
measured by RHI only in subjects with low RHI at baseline. The
provision of dietary nitrate supplementation is a natural, cost
effective strategy that promotes augmentation in systemic NO
synthesis, and reduction in oxLDL and blood lipids when co-
supplemented with vitamin C. Larger randomized trials with a
four-arm design that includes a vitamin C arm are needed for a
comprehensive assessment of the effect of NC on restoring endo-
thelial function using FMD and to confirm the oxidative stress and
lipid modulating properties of NC.
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